Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06418516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Detection of Esophageal Squamous Cancer With the Capsule Sponge Device

Study acronym: ANGELA
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Esophageal squamous cell carcinoma accounts for \~90% of the nearly half-million annual incident cases of esophageal cancer worldwide. The high costs and invasiveness of upper endoscopy constitute a limitation in providing adequate surveillance for at-risk individuals, including those with previous head and neck cancer. The ANGELA study is a prospective evaluation of the minimally-invasive capsule-sponge device, coupled with tissue biomarkers (p53-immunohistochemistry), to detect squamous neoplasia in high-risk individuals.
Trial Details
NCT Number NCT06418516
Lead Sponsor Centre of Postgraduate Medical Education
Collaborators: Maria Sklodowska-Curie National Research Institute of Oncology
Conditions
(from sponsor)		 Esophageal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma
Related terms Carcinoma, Squamous Cell, Esophageal Neoplasms, Head and Neck Neoplasms
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov